formally known as gpha

Same medicine. Same results.
Lower cost.

Biosimilars Council: Patients Can Trust Biosimilars and Providers Can Confidently Prescribe These Medicines

Contact: Steve Arnoff 202.249.7113

WASHINGTON, DC (August 2, 2016) -

Statement by Christine Simmon, Senior Vice President, Policy and Strategic Alliances, GPhA, and Executive Director, Biosimilars Council

"Millions of patients with rheumatoid arthritis, psoriasis and inflammatory bowel disease can be excited today because new research in the Annals of Internal Medicine shows that biosimilars are just as safe and effective as many of the expensive brand biologics prescribed for these conditions.

The Biosimilars Council is pleased to see more science-based evidence that patients can trust biosimilars and that providers can confidently prescribe these medicines. This data reinforces the importance of core scientific principles such as bioequivalence and can help inform policymaker efforts to encourage patient access and promote biosimilar competition."

About the GPhA Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

About GPhA
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at Follow us on twitter: @gpha.